Effect of a Computer-Aided Device for Detecting Gastric Neoplasms: A Multicenter, Randomized Controlled Trial.
무작위 임상시험
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
514 patients were enrolled.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Further real-world studies are needed to fully address the adaptability of AI. (Chinese Clinical Trial Registry, ChiCTR2100054449.).
[BACKGROUND & AIMS] Evidence about the effect of artificial intelligence (AI) on upper endoscopy in multicenter, randomized controlled trials is lacking.
- p-value P = .03
- p-value P < .001
APA
Dong Z, Wu L, et al. (2026). Effect of a Computer-Aided Device for Detecting Gastric Neoplasms: A Multicenter, Randomized Controlled Trial.. Gastroenterology. https://doi.org/10.1053/j.gastro.2025.12.020
MLA
Dong Z, et al.. "Effect of a Computer-Aided Device for Detecting Gastric Neoplasms: A Multicenter, Randomized Controlled Trial.." Gastroenterology, 2026.
PMID
41801173 ↗
Abstract 한글 요약
[BACKGROUND & AIMS] Evidence about the effect of artificial intelligence (AI) on upper endoscopy in multicenter, randomized controlled trials is lacking. We aimed to explore whether AI can enhance gastric neoplasm detection.
[METHODS] Participants from 24 hospitals in China from December 21, 2021, to November 11, 2023, were randomized to AI-assisted or nonassisted esophagogastroduodenoscopy. Primary outcome was detection rate of gastric neoplasms after pathologic review. Secondary outcomes included detection rate of gastric neoplasms before review, relative early gastric cancer detection ratio, detection rate of intestinal metaplasia and/or gastric atrophy before or after review, biopsy rate, number of blind spots, and procedure/inspection time. We did intention-to-treat (ITT), per-protocol, and exploratory subgroup analysis.
[RESULTS] In the ITT cohort, 29,514 patients were enrolled. AI did not improve detection rate of gastric neoplasm after pathological review (RR, 1.13; 0.92-1.38; 1.42 vs 1.25%; P = .25). However, based on original pathology, an improvement with AI was observed (RR, 1.14; 1.0-1.28; 4.06 vs 3.57%; P = .03). AI reduced blind spots number from 2.52 to 1.07 (P < .001) and prolonged procedure and inspection time. No significant differences were observed for relative early gastric cancer detection ratio or detection rate of intestinal metaplasia and/or gastric atrophy before/after pathologic review in ITT cohort. Subgroup analysis suggested potential benefit among less experienced endoscopists and during fatigue periods. In the experimental group, AI diagnosed 100%, 91.9%, and 57.1% of pathologically confirmed gastric adenocarcinoma, high-grade, and low-grade intraepithelial neoplasia, respectively.
[CONCLUSIONS] AI did not improve the detection rate of gastric neoplasms. Further real-world studies are needed to fully address the adaptability of AI. (Chinese Clinical Trial Registry, ChiCTR2100054449.).
[METHODS] Participants from 24 hospitals in China from December 21, 2021, to November 11, 2023, were randomized to AI-assisted or nonassisted esophagogastroduodenoscopy. Primary outcome was detection rate of gastric neoplasms after pathologic review. Secondary outcomes included detection rate of gastric neoplasms before review, relative early gastric cancer detection ratio, detection rate of intestinal metaplasia and/or gastric atrophy before or after review, biopsy rate, number of blind spots, and procedure/inspection time. We did intention-to-treat (ITT), per-protocol, and exploratory subgroup analysis.
[RESULTS] In the ITT cohort, 29,514 patients were enrolled. AI did not improve detection rate of gastric neoplasm after pathological review (RR, 1.13; 0.92-1.38; 1.42 vs 1.25%; P = .25). However, based on original pathology, an improvement with AI was observed (RR, 1.14; 1.0-1.28; 4.06 vs 3.57%; P = .03). AI reduced blind spots number from 2.52 to 1.07 (P < .001) and prolonged procedure and inspection time. No significant differences were observed for relative early gastric cancer detection ratio or detection rate of intestinal metaplasia and/or gastric atrophy before/after pathologic review in ITT cohort. Subgroup analysis suggested potential benefit among less experienced endoscopists and during fatigue periods. In the experimental group, AI diagnosed 100%, 91.9%, and 57.1% of pathologically confirmed gastric adenocarcinoma, high-grade, and low-grade intraepithelial neoplasia, respectively.
[CONCLUSIONS] AI did not improve the detection rate of gastric neoplasms. Further real-world studies are needed to fully address the adaptability of AI. (Chinese Clinical Trial Registry, ChiCTR2100054449.).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- DNA centipede nanowires drive rapid picomolar microRNA detection in cells and serum.
- Hypergolic metal-organic frameworks and metal coordination complexes constructed by dicyandiamide and imidazole derivatives.
- Overcoming multidrug resistance using small molecule dynamic inhibitors by hijacking nascent and inducing turnover of mature ABCG2 for degradation in lysosomes.
- Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy.
- GATA2 Deficiency Syndrome: A Case Series and Literature Review.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.
- Artificial intelligence and breast cancer screening in Serbia: a dual-perspective qualitative study among radiologists and screening-aged women.
- Aesthetically ideal noses created using a single artificial intelligence model: Validating literature and exploring ethnic differences.
- Integrative Computational Approaches to Prostate Cancer with Conditional Reprogramming and AI-Driven Precision Medicine.
- Exploring the Role of Extracellular Vesicles in Pancreatic and Hepatobiliary Cancers: Advances Through Artificial Intelligence.
- From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.